Dynarrestin, a Novel Inhibitor of Cytoplasmic Dynein

Area of Science:

• Cell Biology
• Molecular Biology
• Cancer Research

Background:

• Aberrant hedgehog (Hh) signaling drives multiple cancers.
• Current inhibitors target Smoothened (Smo), but drug resistance emerges due to mutations.
• There is a critical need for inhibitors acting downstream of Smo.

Purpose of the Study:

• To identify and characterize novel inhibitors of Hh signaling downstream of Smo.
• To investigate the mechanism of action and cellular effects of dynarrestin.
• To evaluate dynarrestin's potential as an anti-cancer therapeutic.

Main Methods:

• Identification of dynarrestin as a novel inhibitor of cytoplasmic dyneins 1 and 2.
• In vitro assays to assess dynarrestin's effect on microtubule binding and motility.
• Live-cell imaging to observe dynarrestin's impact on endosome movement and mitosis.
• Analysis of dynarrestin's effect on intraflagellar transport (IFT) and Smo flux in cilia.
• Assessment of dynarrestin's efficacy in suppressing Hh-dependent proliferation.

Main Results:

• Dynarrestin reversibly inhibits cytoplasmic dynein 1-dependent microtubule binding and motility.
• Dynarrestin rapidly and reversibly inhibits endosome movement and perturbs mitosis.
• Dynarrestin inhibits cytoplasmic dynein 2-dependent IFT and Smo flux within cilia without affecting ciliogenesis.
• Dynarrestin suppresses Hh-dependent proliferation of neuronal precursors and tumor cells.

Conclusions:

• Dynarrestin is a novel, reversible inhibitor of cytoplasmic dyneins 1 and 2.
• Dynarrestin effectively inhibits Hh signaling downstream of Smo, impacting key cellular processes.
• Dynarrestin serves as a valuable tool for studying dynein function and shows promise for anti-cancer drug development.